...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Der Pharma Chemica: journal for medicinal chemistry, pharmaceutical chemistry and computational chemistry >Determination of Simultaneous Estimation HPLC Method for Elvitegravir, Tenofovir Disoproxil Fumarate, Emtricitabine and Cobicistat itandrsquo;s Pure And Tablet Form
【24h】

Determination of Simultaneous Estimation HPLC Method for Elvitegravir, Tenofovir Disoproxil Fumarate, Emtricitabine and Cobicistat itandrsquo;s Pure And Tablet Form

机译：Elvitegravir，替诺福韦富马酸替诺福韦，恩曲他滨和安定的Cobicistat同时测定HPLC方法的测定;纯和片剂形式

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A new method was established for simultaneous estimation of elvitegravir, tenofovir, emtricitabine and cobicistat by using Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) method. Chromatographic separations were carried using Inertsil ODS (4.6 × 250 mm, 5 μm) column with a mobile phase composition of 0.1% ortho phosphoric acid buffer and Acetonitrile (30:70) have been delivered at a flow rate of 1 ml/min and the detection was carried out using waters HPLC auto sampler, separation module 2695 with Photo Diode Array (PDA) detector 2996 at wavelength 252 nm. The retention time for elvitegravir, tenofovir, emtricitabine and cobicistat were 2.287, 2.957, 5.652 and 9.801 min respectively. The correlation coefficient values in linearity were found to be 0.999 and concentration range 75-225 μg/ml for elvitegravir, 150- 450 μg/ml for tenofovir, 100-300 μg/ml for emtricitabine and 75-225 μg/ml for cobicistat respectively. The accuracy recovery was found to be 100.11%, 100.26, 100.64 and 100.08% for elvitegravir, tenofovir, emtricitabine and cobicistat respectively. The Limit of Detection (LOD) and Limit of Quantification (LOQ) for Elvitegravir was found to be 2.98 and 9.98, LOD and LOQ for Tenofovir was found to be 3.02 and 10.02, LOD and LOQ for Emtricitabine was found to be 3.00 and 10.00 and LOD and LOQ for Cobicistat was found to be 3.00 and 10.02. The force degradation studies were performed for the dosage form and the results are within the limits. The results of study showed that the proposed RP-HPLC method is a simple, accurate, precise, rugged, robust, fast and reproducible, which may be useful for the routine estimation of elvitegravir, tenofovir, emtricitabine and cobicistat in pharmaceutical dosage form.
机译：建立了一种反相高效液相色谱（RP-HPLC）方法同时评估依维他韦，替诺福韦，恩曲他滨和依比西他汀的新方法。使用Inertsil ODS（4.6×250 mm，5μm）色谱柱进行色谱分离，流动相成分为0.1％的正磷酸缓冲液，以1 ml / min的流速输送乙腈（30:70）使用waters HPLC自动进样器，分离模块2695和光电二极管阵列（PDA）检测器2996在波长252nm下进行检测。 Elvitegravir，tenofovir，恩曲他滨和cobicistat的保留时间分别为2.287、2.957、5.652和9.801分钟。线性相关系数值分别为0.999和Elvitegravir，替诺福韦150-450μg/ ml，恩曲他滨100-300μg/ ml和Cobicistat 75-225μg/ ml的浓度范围为75-225μg/ ml 。 Elvitegravir，tenofovir，emtricitabine和cobicistat的准确率回收率分别为100.11％，100.26、100.64和100.08％。 Elvitegravir的检出限（LOD）和定量限（LOQ）为2.98和9.98，替诺福韦的LOD和LOQ为3.02和10.02，恩曲他滨的LOD和LOQ为3.00和10.00， Cobicistat的LOD和LOQ为3.00和10.02。对剂型进行了力降解研究，结果在极限范围内。研究结果表明，所提出的RP-HPLC方法简便，准确，精确，稳定，可靠，快速，可重现，可用于药物剂型中elvitegravir，tenofovir，emtricitabine和cobicistat的常规估算。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号